Literature DB >> 30747371

Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.

Elizabeth Donovan1, Patricia Case2, Jeffrey P Bratberg3, Janette Baird4, Dina Burstein4, Alexander Y Walley5, Traci C Green6,7.   

Abstract

Drug overdose is the leading cause of unintentional death in the USA and the majority of deaths involve an opioid. Pharmacies are playing an increasingly important role in getting naloxone-the antidote to an opioid overdose-into the community. The aim of the current study was to understand, from the perspective of those who had obtained naloxone at the pharmacy, whose drug using status and pain patient status was not known until the interviews were conducted, as well as those who had not obtained naloxone at the pharmacy but were at risk for overdose, factors that impact the likelihood of obtaining pharmacy-based naloxone (PBN). Fifty-two participants from two New England states were interviewed between August 2016 and April 2017. We used a phenomenological approach to investigate participants' beliefs about pharmacy-based naloxone. The social contextual model was chosen to structure the collection and analysis of the qualitative data as it takes into account individual, interpersonal, organizational (pharmacy), community, and societal influences on a specific health behavior. Of the 52 people interviewed, 24 participants had obtained naloxone from the pharmacy in the past year, of which 4% (n = 1) self-disclosed during the interview current illicit drug use and 29% (n = 7) mentioned using prescribed opioid pain medication. Of the 28 people who had not obtained naloxone from the pharmacy, 46% (n = 13) had obtained an over the counter syringe from a pharmacy in the past month and had used an opioid in the past month, and 54% (n = 15) had used a prescribed opioid pain medication in the past month but did not report a syringe purchase. Several main themes emerged from the interview data. Individual-level themes were as follows: helplessness and fear, naloxone as empowerment to help, and past experiences at the pharmacy. Interpersonal-level themes were as follows: concern for family and friends, and sources of harm reduction information. Themes associated with pharmacy-level influence were as follows: perceived stigma from pharmacists, confusion at the pharmacy counter, and receptivity to pharmacists' offer of naloxone; community-level themes were as follows: community caretaking and need for education and training. Finally, themes at the societal-level of influence were as follows: generational crisis, and frustration at lack of response to opioid crisis. Overall our findings reveal factors at multiple levels which may play a role in likelihood of obtaining naloxone at the pharmacy. These factors can be used to inform interventions seeking to increase provision of pharmacy-based naloxone.

Entities:  

Keywords:  Interviews; Naloxone; Opioid; Overdose; Pharmacy; Qualitative; USA

Year:  2019        PMID: 30747371      PMCID: PMC6565759          DOI: 10.1007/s11524-019-00349-1

Source DB:  PubMed          Journal:  J Urban Health        ISSN: 1099-3460            Impact factor:   3.671


  11 in total

1.  Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina.

Authors:  Prasana Khatiwoda; Rae Jean Proeschold-Bell; Christina S Meade; Lawrence P Park; Scott Proescholdbell
Journal:  N C Med J       Date:  2018 May-Jun

2.  Choose your method: a comparison of phenomenology, discourse analysis, and grounded theory.

Authors:  Helene Starks; Susan Brown Trinidad
Journal:  Qual Health Res       Date:  2007-12

3.  Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.

Authors:  Thomas J Stopka; Ashley Donahue; Marguerite Hutcheson; Traci C Green
Journal:  J Am Pharm Assoc (2003)       Date:  2017-02-08

4.  Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.

Authors:  Traci C Green; Patricia Case; Haley Fiske; Janette Baird; Shachan Cabral; Dina Burstein; Victoriana Schwartz; Nathan Potter; Alexander Y Walley; Jeffrey Bratberg
Journal:  J Am Pharm Assoc (2003)       Date:  2017-02-14

5.  Medications For Addiction Treatment: Changing Language to Improve Care.

Authors:  Sarah E Wakeman
Journal:  J Addict Med       Date:  2017 Jan/Feb       Impact factor: 3.702

6.  Model for incorporating social context in health behavior interventions: applications for cancer prevention for working-class, multiethnic populations.

Authors:  Glorian Sorensen; Karen Emmons; Mary Kay Hunt; Elizabeth Barbeau; Roberta Goldman; Karen Peterson; Karen Kuntz; Anne Stoddard; Lisa Berkman
Journal:  Prev Med       Date:  2003-09       Impact factor: 4.018

7.  Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.

Authors:  Traci C Green; Emily F Dauria; Jeffrey Bratberg; Corey S Davis; Alexander Y Walley
Journal:  Harm Reduct J       Date:  2015-08-06

8.  Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis.

Authors:  Alexander Y Walley; Ziming Xuan; H Holly Hackman; Emily Quinn; Maya Doe-Simkins; Amy Sorensen-Alawad; Sarah Ruiz; Al Ozonoff
Journal:  BMJ       Date:  2013-01-30

Review 9.  Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists.

Authors:  Jamie K Lim; Jeffrey P Bratberg; Corey S Davis; Traci C Green; Alexander Y Walley
Journal:  J Addict Med       Date:  2016 Sep-Oct       Impact factor: 3.702

10.  Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016.

Authors:  B E Meyerson; J D Agley; A Davis; W Jayawardene; A Hoss; D J Shannon; P T Ryder; K Ritchie; R Gassman
Journal:  Drug Alcohol Depend       Date:  2018-04-26       Impact factor: 4.492

View more
  15 in total

1.  Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.

Authors:  Robin A Pollini; Susannah Slocum; Jenny Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2021-08-23

2.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

3.  Gaps in naloxone ownership among people who inject drugs during the fentanyl wave of the opioid overdose epidemic in New York City, 2018.

Authors:  Alexis V Rivera; Michelle L Nolan; Denise Paone; Sidney A Carrillo; Sarah L Braunstein
Journal:  Subst Abus       Date:  2022       Impact factor: 3.984

4.  Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.

Authors:  Robin A Pollini; Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley
Journal:  J Am Pharm Assoc (2003)       Date:  2022-03-19

5.  Australian Community Pharmacy Harm-Minimisation Services: Scope for Service Expansion to Improve Healthcare Access.

Authors:  Sara S McMillan; Hidy Chan; Laetitia H Hattingh
Journal:  Pharmacy (Basel)       Date:  2021-04-26

6.  Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?

Authors:  Scott G Weiner; Jason A Hoppe
Journal:  Jt Comm J Qual Patient Saf       Date:  2021-04-04

7.  A free mailed naloxone program in Philadelphia amidst the COVID-19 pandemic.

Authors:  Rachel French; Jamie Favaro; Shoshana V Aronowitz
Journal:  Int J Drug Policy       Date:  2021-03-04

8.  Effectiveness and implementability of state-level naloxone access policies: Expert consensus from an online modified-Delphi process.

Authors:  Rosanna Smart; Sean Grant
Journal:  Int J Drug Policy       Date:  2021-07-30

9.  Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone" [Response To Letter].

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-07-09

10.  Naloxone Prescriptions Among Commercially Insured Individuals at High Risk of Opioid Overdose.

Authors:  Sarah Follman; Vineet M Arora; Chris Lyttle; P Quincy Moore; Mai T Pho
Journal:  JAMA Netw Open       Date:  2019-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.